<DOC>
	<DOCNO>NCT00206648</DOCNO>
	<brief_summary>The purpose study determine difference prevent relapse Betaseron Avonex . Patients RRMS currently treat Avonex randomize 2 equal-size arm ; one arm continue standard dose Avonex ; one arm convert Betaseron standard dose .</brief_summary>
	<brief_title>An Efficacy Safety Comparison Study Two Marketed Drugs Patients With Relapsing-remitting MS</brief_title>
	<detailed_description>This study previously post Berlex , Inc. Berlex , Inc. rename Bayer HealthCare Pharmaceuticals , Inc.Bayer HealthCare Pharmaceuticals , Inc.is sponsor trial .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>RRMS patient receive treatment Avonex 30 Âµg weekly Primary Progressive Secondary Progressive MS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>